Pfizer-BioNTech vaccine shows promise

Pfizer-BioNTech vaccine shows promise

Pfizer-BioNTech vaccine shows promise

Oxford University have discovered their vaccine can 'train the immune system'. Scientists at Oxford University say their experimental coronavirus vaccine has been shown in an early trial to prompt a protective immune response in hundreds of people who got the shot.

But what does the vaccine do, how does it work, and what happens next?

The vaccine has been produced by British-Swedish multinational pharmaceutical and biopharmaceutical company AstraZeneca.

Clinical trials of a Russia COVID-19 vaccine developed by the Gamaleya Scientific Research Institute of Epidemiology and Microbiology jointly with the Russian Defence Ministry are wrapping up at the Burdenko Main Military Clinical Hospital.

Researchers at Oxford University have confirmed that a vaccine, which is in the early stages of development, has shown promise. "What this vaccine does particularly well is trigger both arms of the immune system", he said.

Prof Chris Whitty, Chief Medical Officer, said: "Now that there are several promising vaccines on the horizon, we need to call again on the generosity of the public to help find out which potential vaccines are the most effective". The efficacy of the vaccine and expediting the trail would depend on if everything goes well- or else we will be back to the drawing board - so we are6 taking that risk.

The first COVID-19 vaccine to succeed in medical trials in people was chose to be each protected and generate an immune response in opposition to the virus - a "milestone" in the battle to defeat the lethal bug, a brand new research discovered.

The results from human trials into the vaccine, published today in the Lancet, showed that it provoked a T-cell response within 14 days of vaccination and an antibody response within 28 days. It has said it will not seek to profit from the vaccine during the pandemic. But the body thinks that there is a virus and starts producing antibodies.

"Even 2 billion doses may not be enough", he said, pointing to the ongoing surge of infections worldwide. "It would be very unlucky if all of them fail", Swaminathan added.

To ensure that the vaccine would work well against COVID-19, a much larger trial consisting of 10,000 people from the UK, South Africa, and Brazil is now happening.

With no working vaccine against COVID-19 yet developed, Britain now has three different types of vaccine under order and a total of 230 million doses potentially available.

A new NHS Covid-19 vaccine research registry has also been established with the aim of recruiting 500,000 volunteers by October to test new vaccines and treatments.

All those who took part in Phase-I and II trials for the vaccine, which took place in China, generated antibodies against the virus after being given the vaccine.

There is much speculation as to whether North Korea has the skills to develop a vaccine as so little is known about the country's level of medical care.

The whole world is waiting impatiently at this time.

"But one of the worrying patterns we see is some countries moving in the other direction", he warned. The age group of the study population is 18 to 55 years.

Two sources told Reuters on Friday the European Union was negotiating advance purchase deals of potential COVID-19 vaccines with drugmakers Moderna, Sanofi and Johnson & Johnson, as well as biotech firms BioNTech and CureVac.

The vaccine being developed by Pfizer also works to trigger a similar dual immune response as the Oxford shot.

In fact, on Sunday, Richard had tweeted that "On Monday the results of the vaccine being made for the coronavirus will be announced". The first dose of vaccine likely to be administered to volunteers on Thursday, AIR news reported Dr. Rai as saying.

Related news



[an error occurred while processing the directive]